Gates Remains Among the Few in Philanthropy to Drive Research for an HIV Vaccine

Gates Remains Among the Few in Philanthropy to Drive Research for an HIV Vaccine

Philanthropy makes up only a small fraction of spending on research and support for people with HIV, still a major threat around the world. In the push for a vaccine, Gates and Gilead are leading the pack.

Read More

IP Briefing: What’s Going on with Philanthropy for LGBTQ+ Issues?

IP Briefing: What’s Going on with Philanthropy for LGBTQ+ Issues?

Funding for U.S.-based nonprofits focused on LGBTQ+ communities is on the rise, yet this sector still receives only a tiny fraction of overall giving. Here’s an overview of the space, with plenty of links to our coverage on the topic.

Read More

It Takes More Than Science: A Drugmaker's Philanthropy Focuses on Health Equity

It Takes More Than Science: A Drugmaker's Philanthropy Focuses on Health Equity

With the pandemic shedding further light on the many social factors that shape health inequality, the Gilead Foundation is launching a three-pronged funding program to advance health justice.

Read More

We Want to Do Our Part: A Corporate Funder Steps up for Trans Communities

We Want to Do Our Part: A Corporate Funder Steps up for Trans Communities

Transgender communities face inordinate challenges, but receive a small slice of philanthropic funding. With a new grantmaking program that draws on input from the trans community, Gilead Sciences is helping to change that.

Read More

Hot Zone: How a Drugmaker is Taking on HIV/AIDS in the South

Hot Zone: How a Drugmaker is Taking on HIV/AIDS in the South

Gilead Sciences is a leading player in HIV/AIDS funding in the U.S. South, with a major grantmaking program aimed at tackling an epidemic that’s still raging in this part of the country. Where’s the money going?

Read More

So Close, Yet So Far: Why is HIV/AIDS Funding Decreasing?

So Close, Yet So Far: Why is HIV/AIDS Funding Decreasing?

Nearly 1 million people die annually from HIV/AIDS, despite antiretroviral drugs that can extend their lives. And while the world’s billionaires sit on trillions of dollars, private donors are doing less to combat the epidemic. What’s going on here?

Read More

The Corporate Funder Giving New Attention to HIV/AIDS in the American South

The Corporate Funder Giving New Attention to HIV/AIDS in the American South

Gilead Sciences recently announced a 10-year, $100 million commitment to combat HIV/AIDS in the South—the latest funder to respond to a disturbingly high prevalence of infections in the region. 

Read More

Refugee Funding Gets a Boost from an Unexpected Source

Refugee Funding Gets a Boost from an Unexpected Source

We don't think of Gilead Sciences as a player in the refugee space, but it made a nice give last month to address the health needs of displaced Syrians. 

Read More